Validation of Hepa-index as a non-invasive biomarkers panel for assessment of hepatic fibrosis in Egyptians with chronic hepatitis C

References

1. ↵
   1. AASLD/IDSA HCV Guidance Panel

   (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932–954.

   OpenUrlCrossRefPubMed
2. ↵
   1. Patel K,
   2. Bedossa P,
   3. Castera L

   (2015) Diagnosis of liver fibrosis: present and future. Semin Liver Dis 35:166–183.

   OpenUrlCrossRefPubMed
3. ↵
   1. Wedemeyer H,
   2. Duberg AS,
   3. Buti M,
   4. Rosenberg WM,
   5. Frankova S,
   6. Esmat G,
   7. et al.

   (2014) Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21:60–89.

   OpenUrlCrossRefPubMed
4. ↵
   1. Ito T,
   2. Kumada T,
   3. Toyoda H,
   4. Tada T,
   5. Kiriyama S,
   6. Tanikawa M,
   7. et al.

   (2015) Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. J Viral Hepat 22:777–783.

   OpenUrl
5. ↵
   1. Bedossa P,
   2. Patel K,
   3. Castera L

   (2015) Histologic and noninvasive estimates of liver fibrosis. Clinical Liver Disease 6:5–8.

   OpenUrl
6. ↵
   1. European Association for Study of Liver;Asociacion Latinoamericana para el Estudio del Higado

   (2015) EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63:237–264.

   OpenUrlCrossRefPubMed
7. ↵
   1. Yang L,
   2. Rudser KD,
   3. Higgins L,
   4. Rosen HR,
   5. Zaman A,
   6. Corless CL,
   7. et al.

   (2011) Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Dig Dis Sci 56:3305–3315.

   OpenUrlPubMed
8. ↵
   1. Fallatah HI

   (2014) Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014:1–15.

   OpenUrl
9. ↵
   1. Powell EE,
   2. Edwards-Smith CJ,
   3. Hay JL,
   4. Clouston AD,
   5. Crawford DH,
   6. Shorthouse C,
   7. et al.

   (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31:828–833.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Wai CT,
    2. Greenson JK,
    3. Fontana RJ,
    4. Kalbfleisch JD,
    5. Marrero JA,
    6. Conjeevaram HS,
    7. et al.

    (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38:518–526.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Sterling RK,
    2. Lissen E,
    3. Clumeck N,
    4. Sola R,
    5. Correa MC,
    6. Montaner J,
    7. et al.

    (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Poynard T,
    2. Morra R,
    3. Halfon P,
    4. Castera L,
    5. Ratziu V,
    6. Imbert-Bismut F,
    7. et al.

    (2007) Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 7:40.

    OpenUrlCrossRefPubMed
13. ↵
    1. Alboraie M,
    2. Khairy M,
    3. Elsharkawy A,
    4. Asem N,
    5. El Kassas M,
    6. Elghamry F,
    7. et al.

    (2015) P0520 : Acceptability, reliability and applicability of liver biopsy and non-invasive methods for assessment of hepatic fibrosis and cirrhosis among hepatologists;a web based survey. Journal of Hepatology 62:S510.

    OpenUrl
14. ↵
    1. Alboraie M,
    2. Schütte K,
    3. Wex T,
    4. Kahl S,
    5. Adolf D,
    6. Selgrad M,
    7. et al.

    (2012) Hepa-index, a New Biomarker Indicator of Hepatic Fibrosis in Patients with Chronic Liver Disease. Journal of Gastroenterology and Hepatology Research 1:204–209.

    OpenUrl
15. ↵
    1. Poynard T,
    2. Ratziu V,
    3. Benmanov Y,
    4. Di Martino V,
    5. Bedossa P,
    6. Opolon P

    (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20:47–55.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Bedossa P,
    2. Poynard T

    (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289–293.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    1. Fontana RJ,
    2. Dienstag JL,
    3. Bonkovsky HL,
    4. Sterling RK,
    5. Naishadham D,
    6. Goodman ZD,
    7. et al.

    (2010) Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 59:1401–1409.

    OpenUrlAbstract/FREE Full Text
18. ↵
    1. Poynard T,
    2. Moussalli J,
    3. Munteanu M,
    4. Thabut D,
    5. Lebray P,
    6. Rudler M,
    7. et al.

    (2013) Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 59:675–683.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Liu T,
    2. Wang X,
    3. Karsdal MA,
    4. Leeming DJ,
    5. Genovese F

    (2012) Molecular serum markers of liver fibrosis. Biomark Insights 7:105–117.

    OpenUrlCrossRefPubMed
20. ↵
    1. Castera L

    (2011) Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int 5:625–634.

    OpenUrlCrossRefPubMed
21. ↵
    1. Calès P,
    2. Veillon P,
    3. Konaté A,
    4. Mathieu E,
    5. Ternisien C,
    6. Chevailler A,
    7. et al.

    (2008) Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 41:10–18.

    OpenUrlCrossRefPubMed